The ZEST trial, a phase 3 study on MRD-guided therapy in breast cancer, was terminated early due to low randomization rates. ctDNA was most frequently detected within six months post-treatment, ...
Prognosis of patients with HER2-low breast cancer brain metastasis: A single-institution experience. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not ...
C9581 evaluated edrecolomab versus observation in patients with stage II CC and reported no survival benefit. Under an initial case-cohort sampling design, a randomly selected subcohort (RS) comprised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results